fore8394
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2022 (NCT05503797)
Timeline
Indications
Mechanism of action
- BRAF/CRAFINHIBITOR
BRAF/CRAF inhibitor
Serine/threonine-protein kinase B-raf inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12- Mol. weight
- 542.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303729 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06610682 | Phase 1 | Nov 15, 2024 | Johns Hopkins University, Novellus Therapeutics |
| NCT06385119 | Phase 1 | Apr 24, 2024 | Novellus Therapeutics |
| NCT05503797 | Phase 2 | Nov 1, 2022 | Novellus Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novellus Therapeutics | For profit | 3 | 2 | 2 | 2022 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1